Key result
Bevifibatide is not cost-effective compared to eptifibatide for ACS patients undergoing PCI.
Why the study?
The cost-effectiveness of bevifibatide compared to eptifibatide for ACS patients undergoing PCI in China was uncertain.
Is bevifibatide cost-effective compared to eptifibatide for acute coronary syndrome patients undergoing percutaneous coronary intervention in China?
Is bevifibatide cost-effective compared to eptifibatide for acute coronary syndrome patients undergoing percutaneous coronary intervention in China?
At its current price, bevifibatide is not cost-effective compared to eptifibatide for ACS patients undergoing PCI in China, requiring a price reduction to approximately ¥595/vial to achieve cost-effectiveness.
Answers are grounded in this paper and cite their sources.
Does not support bevifibatide adoption at current pricing for ACS-PCI in China; leaves open price thresholds for future cost-effectiveness analyses.
This study evaluated the cost-effectiveness of bevifibatide versus eptifibatide for acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) in China. A 30-day decision tree and 15-year Markov model simulated outcomes using matching-adjusted indirect comparison data. Base-case analysis used current listed price of bevifibatide (¥1290/vial). Costs and quality-adjusted life-years (QALYs) were evaluated against willingness-to-pay (WTP) thresholds based on China's per capita gross domestic product (GDP). Base-case results showed bevifibatide added ¥12,909.24 and 0.0595 QALYs, yielding an incremental cost-effectiveness ratio (ICER) of ¥216,899/QALY. This significantly exceeds the ¥76,599 WTP threshold (0.8 times GDP), indicating it is not cost-effective. Lifetime analysis confirmed these results (ICER: ¥159,541/QALY). Threshold analysis indicated a price reduction to approximately ¥595/vial is required to achieve cost-effectiveness. In conclusion, bevifibatide is not cost-effective for ACS patients undergoing PCI in China at its current price. A substantial price reduction is necessary to align cost with clinical value, providing an evidence-based threshold for future reimbursement negotiations.
No takes yet. Share an insight, caveat, or question.
Yao et al. (2026) studied Acute coronary syndrome (ACS). Bevifibatide vs. Eptifibatide was evaluated on Incremental cost-effectiveness ratio (ICER) per QALY gained (ICER ¥216,899/QALY). Bevifibatide was not cost-effective compared to eptifibatide for ACS patients undergoing PCI in China, yielding an incremental cost-effectiveness ratio of ¥216,899/QALY.
Synapse has enriched 10 related papers. Consider them for comparative context: